Page 330 - Read Online

Flynn et al. J Cancer Metastasis Treat 2019;5:43 I http://dx.doi.org/10.20517/2394-4722.2019.13 Page 7 of 12

Table 1. Cancer clinical trials evaluating autophagy modulation
Clincial trial title Status Conditions Interventions
Autophagy Bladder Cancer Not yet recruiting Bladder Cancer
Sorafenib Induced Autophagy Using Recruiting Hepatocellular Cancer Drug: Sorafenib (SOR)|Drug:
Hydroxychloroquine in Hepatocellular Cancer Hydroxychloroquine (HCQ)
A Phase I/II/Pharmacodynamic Study of Active, not Advanced Adenocarcinoma|Metastatic Drug: Hydroxychloroquine
Hydroxychloroquine in Combination With recruiting Adenocarcinoma (HCQ)|Drug: Gemcitabine
Gemcitabine/Abraxane to Inhibit Autophagy
in Pancreatic Cancer
Hydroxychloroquine, Palbociclib, and Recruiting Anatomic Stage I Breast Cancer AJCC Drug: Hydroxychloroquine|Drug:
Letrozole Before Surgery in Treating v8|Anatomic Stage IA Breast Cancer Letrozole|Drug: Palbociclib
Participants With Estrogen Receptor Positive, AJCC v8|Anatomic Stage IB Breast
HER2 Negative Breast Cancer Cancer AJCC v8|Anatomic Stage II
Breast Cancer AJCC v8|Anatomic Stage
IIA Breast Cancer AJCC v8|Anatomic
Stage IIB Breast Cancer AJCC
v8|Anatomic Stage III Breast Cancer
AJCC v8|Anatomic Stage IIIA Breast
Cancer AJCC v8|Anatomic Stage IIIB
Breast Cancer AJCC v8|Anatomic Stage
IIIC Breast Cancer AJCC v8|Anatomic
Stage IV Breast Cancer AJCC
v8|Estrogen Receptor Positive|HER2/Neu
Negative|MKI67 Positive|Postmenopaus
al|Prognostic Stage I Breast Cancer AJCC
v8|Prognostic Stage IA Breast Cancer
AJCC v8|Prognostic Stage IB Breast
Cancer AJCC v8|Prognostic Stage IIA
Breast Cancer AJCC v8|Prognostic Stage
IIB Breast Cancer AJCC v8|Prognostic
Stage III Breast Cancer AJCC
v8|Prognostic Stage IIIA Breast Cancer
AJCC v8|Prognostic Stage IIIB Breast
Cancer AJCC v8|Prognostic Stage IIIC
Breast Cancer AJCC v8|Prognostic Stage
IV Breast Cancer AJCC v8
Imaging Tumor Hypoxia With 18F-EF5 PET in Active, not Ovarian Cancer|Ovarian Neoplasms Drug: 18F-EF5 PET/CT
Recurrent or Metastatic Clear Cell Ovarian recruiting scan|Procedure: Optional biopsy
Cancer
Enzalutamide and Metformin Hydrochloride Active, not Prostate Cancer Drug: Enzalutamide|Drug: Metformin
in Treating Patients With Hormone-Resistant recruiting Hydrochloride
Prostate Cancer
Vorinostat Plus Hydroxychloroquine Versus Recruiting Colorectal Cancer Drug: Vorinostat|Drug:
Regorafenib in Colorectal Cancer Hydroxychloroquine|Drug:
Regorafenib
Sirolimus or Vorinostat and Active, not Advanced Cancers Drug: Hydroxychloroquine|Drug:
Hydroxychloroquine in Advanced Cancer recruiting Sirolimus|Drug: Vorinostat
MLN9708 and Vorinostat in Patients With Active, not Advanced Cancers Drug: MLN9708|Drug: Vorinostat
Advanced p53 Mutant Malignancies recruiting
Akt Inhibitor MK2206 and Active, not Adult Solid Neoplasm|Hormone- Drug: Akt Inhibitor MK2206|Drug:
Hydroxychloroquine in Treating Patients With recruiting Resistant Prostate Carcinoma|Recurrent Hydroxychloroquine|Other:
Advanced Solid Tumors, Melanoma, Prostate Melanoma|Recurrent Prostate Laboratory Biomarker Analysis|Other:
or Kidney Cancer Carcinoma|Recurrent Renal Cell Pharmacological Study
Carcinoma|Stage IIIA Cutaneous
Melanoma AJCC v7|Stage IIIB Cutaneous
Melanoma AJCC v7|Stage IIIC Cutaneous
Melanoma AJCC v7|Stage IV Cutaneous
Melanoma AJCC v6 and v7|Stage IV
Prostate Cancer AJCC v7|Stage IV Renal
Cell Cancer AJCC v7
Hydroxychloroquine + Vorinostat in Active, not Malignant Solid Tumour Drug: Hydroxychloroquine|Drug:
Advanced Solid Tumors recruiting Vorinostat
Novel Molecular Targets for Ductal Active, not Breast Cancer Other: Biomarkers
Carcinoma In Situ (DCIS) recruiting
Observational Study of Biomarker During Recruiting Liver Cancer|Hepatobiliary Tract Procedure: Hepatocellular carcinoma
Liver Surgery Adenomas and Carcinomas
Pantoprazole and Docetaxel for Men With Active, not Prostate Cancer Drug: Pantoprazole
Metastatic Castration-Resistant Prostate recruiting
Cancer